Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa. (15th November 2022)

• Record Type: Journal Article
• Authors: Waalewijn, Hylke; Stol, Kim; van der Knaap, Linda; Fraaij, Pieter L.A.; Vermont, Clementien; van Rossum, Annemarie M.C.; Strik-Albers, Riet; Burger, David M.; Svensson, Elin M.; Colbers, Angela
• Is Part Of: AIDS. Volume 36:Number 14(2022)
• Page Start: 2077
• Page End: 2079
• Publication Date: 2022-11-15
• Subjects: AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003350
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Dolutegravir 50 mg is registered for use in children weighing 20–40 kg. This approval is based on data from an African paediatric cohort, and no pharmacokinetic data was available from children outside of Africa. This study provides further evidence of the effective use of dolutegravir 50 mg in children weighing 20 to 40 kg by showing that concentration data gathered in clinical practice shows adequate concentration levels in Dutch children without a safety signal.